Literature DB >> 16167545

Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.

O Ozen1, B Demirhan, N Altinörs.   

Abstract

OBJECTIVE: Meningiomas for the most part are slow-growing benign tumors, but complete removal can be difficult and recurrence is an issue. The aim of this study was to re-evaluate tumors diagnosed as meningioma previously in our hospital, according to the latest World Health Organization classification. We also examined the relationships among parameters such as brain invasion, histological grade and Ki-67 and p53 expression in these tumors.
MATERIALS AND METHODS: Meningioma biopsy specimens numbering 60 (48 grade I, 11 grade II, and 1 grade III tumors) were examined immunohistochemically using monoclonal antibodies for Ki-67 (MIB-1) and p53 protein. The MIB-1 labeling index (LI) for each tumor was calculated as a percentage based on the number of stained cells per total cells counted. The level of p53 expression in each sample was semiquantatively evaluated as < 1%, 1 - 10%, 10 - 70%, or > 70%. Any value > 1% was accepted as presence of p53 expression.
RESULTS: Of the 60 meningiomas, 7 (11.7%) exhibited brain invasion. The mean MIB-1 LI values for the grade I and grade II tumors were 1.1% and 2.3%, respectively. The corresponding levels of p53 protein expression in these groups were 54.1% and 72.7%. The MIB-1 LI and the level of p53 expression in the one grade III meningioma were 6.7% and 10 - 70%, respectively. Histological grade was significantly correlated with MIB-1 LI and with p53 expression (p < 0.01 for both). Brain invasion was not correlated with histological grade, MIB-1 LI, or p53 expression.
CONCLUSION: The results indicate that MIB-1 LI and p53 protein expression are good indicators of histological grade in meningioma and may be particularly valuable for distinguishing borderline atypical meningiomas. The number of cases was limited, but the findings also suggest that brain invasion is a prognostic parameter independent of grade, MIB-1 LI and p53 expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16167545

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  8 in total

Review 1.  Prognostic significance of brain invasion in meningiomas: systematic review and meta-analysis.

Authors:  Satoshi Nakasu; Yoko Nakasu
Journal:  Brain Tumor Pathol       Date:  2021-01-06       Impact factor: 3.298

Review 2.  Pediatric meningioma: current approaches and future direction.

Authors:  Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo
Journal:  J Neurooncol       Date:  2011-01-04       Impact factor: 4.130

Review 3.  A review of malignant meningiomas: diagnosis, characteristics, and treatment.

Authors:  Simon Hanft; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2010-08-21       Impact factor: 4.130

4.  Pediatric versus adult meningioma: comparison of epidemiology, treatments, and outcomes using the Surveillance, Epidemiology, and End Results database.

Authors:  Roy W R Dudley; Michelle R Torok; Sarah Randall; Benjamin Béland; Michael H Handler; Jean M Mulcahy-Levy; Arthur K Liu; Todd C Hankinson
Journal:  J Neurooncol       Date:  2018-03-09       Impact factor: 4.130

5.  Loss of p53 expression is accompanied by upregulation of beta-catenin in meningiomas: a concomitant reciprocal expression.

Authors:  Nives Pećina-Šlaus; Anja Kafka; Tomislav Vladušić; Davor Tomas; Monika Logara; Josip Skoko; Reno Hrašćan
Journal:  Int J Exp Pathol       Date:  2016-06-12       Impact factor: 1.925

6.  A role for the p53 pathway in the pathology of meningiomas with NF2 loss.

Authors:  ZeNan Chang; Chin-Lin Guo; Iris Ahronowitz; Anat O Stemmer-Rachamimov; Mia MacCollin; Fabio P Nunes
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

Review 7.  Meningioma recurrence.

Authors:  Tibor Hortobágyi; János Bencze; Gréta Varkoly; Mahan C Kouhsari; Álmos Klekner
Journal:  Open Med (Wars)       Date:  2016-06-09

8.  Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance.

Authors:  Anja Bukovac; Anja Kafka; Reno Hrašćan; Tomislav Vladušić; Nives Pećina-Šlaus
Journal:  Mol Clin Oncol       Date:  2019-10-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.